Today, investors in Fulcrum Therapeutics (NASDAQ:FULC) are seeing explosive gains. Indeed, shares of this clinical stage biopharma company have skyrocketed. Currently, shares of FULC stock are up around 140% at the time of writing on extremely heavy volume. Source: Shutterstock Today’s move brings FULC stock to a new 52-week high and puts this company within spitting distance…